Cocrystal(COCP) - 2024 Q2 - Quarterly Results

Exhibit 99.1 1 Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs ● Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial indication of virology ● In vitro testing shows CC-42344 inhibits the avian influenza A (H5N1) PB2 protein recently identified in U.S. dairy cows ● Expects to report topline results in late 2024 or early 2025 from Phase 1 study with oral CD ...